國家衛生研究院 NHRI:Item 3990099045/14183
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 907905      在线人数 : 917
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/14183


    题名: Development of COVID-19 vaccines through augmenting antiviral immune responses: A systematic review and meta-analysis
    作者: Ma, KSK;Lee, CC;Liu, KJ;Wang, LT
    贡献者: National Institute of Cancer Research
    摘要: We aim to evaluate strategies on augmentation of host immunity against Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) infection. We searched clinical trials registered at the National Institutes of Health through December, 2020, and conducted analyses on inoculated population, involved immunological processes, source of injected components, and trial phases. We then searched PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials for their corresponding reports. A bivariate random‐ effects meta‐analysis was used to derive the pooled estimate of seroconversion and adverse events (AEs). A total of 540,269 participants were enrolled in 225 identified trials. The working mechanisms included heterologous immunity, active immunity, passive immunity, and immunotherapy. A total of 2,565 healthy adults from 10 clinical trials were included for meta‐analyses. The odd ratio (OR) was 90.82 for kinetics of serologic responses to anti‐SARS‐CoV‐2 antibody IgG titer (95% CI =36.1 – 228.49; p< 0.00001). The pooled ORs were 2.57 for solicited systemic AEs (95%CI =1.57 – 4.21; p = 0.0002), 5.72 for solicited local AEs (95% CI=2.59 – 12.67; p < 0.0001), and 2.08 for unsolicited systemic events (95% CI=1.42 – 3.05; p = 0.0002), compared to placebo or conservative treatment. Among all immune‐augmentative interventions, a paradigm shift to vaccines providing active immunity was observed. The efficacy of these interventions was promising although systemic adverse events were noted.
    日期: 2021-08
    關聯: European Journal of Immunology. 2021 Aug;51(Suppl. 1):395.
    Link to: http://dx.doi.org/10.1002/eji.202170200
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0014-2980&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000753366402130
    显示于类别:[劉柯俊] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000753366402130.pdf222KbAdobe PDF226检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈